NCI NCTN-Network Lead Academic Site at UPCI
NCI NCTN-Network Lead Academic Site at UPCI
批准号:
8605956
负责人:
ADAM M BRUFSKY
金额:
$94.57万
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-04-24 至 2019-02-28
关键词:
AccountingAffectAmericanAmerican College of Surgeons Oncology GroupBasic ScienceCancer BurdenCaringCause of DeathCessation of lifeClinical ResearchClinical TreatmentClinical TrialsClinical Trials Cooperative GroupClinical Trials NetworkCommunity Clinical Oncology ProgramComprehensive Cancer CenterConduct Clinical TrialsCooperative Group ProgramDetectionDevelopmentDiagnosisDoctor of PhilosophyEastern Cooperative Oncology GroupEducationExpenditureFundingFutureGynecologic Oncology GroupHeart DiseasesInstitute of Medicine (U.S.)InstitutionLeadLeadershipMalignant NeoplasmsMedicalMulti-Institutional Clinical TrialNational Surgical Adjuvant Breast and Bowel ProjectPennsylvaniaPhysiciansPositioning AttributePreventionProcessProgress ReportsPublic HealthRadiation Therapy Oncology GroupRecommendationRelative (related person)Research InfrastructureResearch PersonnelScienceSiteSurvival RateTranslational ResearchUnited StatesUniversity of Pittsburgh Cancer Institutebasecancer carecancer diagnosiscancer therapycostimprovednext generationprogramspublic health relevancesoundtreatment trialtrend
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): For more than 50 years, the NCI has supported a clinical trials infrastructure [the NCI National Clinical Trials Cooperative Group Program (CTCGP)] to conduct large-scale, clinical treatment trials across the nation. As part of its effort
to take advantage of new discoveries in oncologic sciences, the NCI asked the Institute of Medicine (lOM) in 2009 to review the NCI-sponsored CTCGP. Based on the lOM review recommendations, as well as additional input received from stakeholders across the oncology community, the NCI has developed a comprehensive plan to transform the previous CTCGP that funded several separate organizations conducting cancer treatment trials into a new consolidated and integrated Program referred to as the NCI National Clinical Trials Network (NCTN). The University of Pittsburgh Cancer Institute (UPCI) has been an NCI-designated Comprehensive Cancer Center since 1990. The UPCI has led ably and participated in several NCI CTCGPs, including ECOG, NSABP, RTOG, GOG, and ACOSOG. The UPCI now plans to participate under the new NCI NCTN as a Lead Academic Site. We propose to participate in NCTN as a Network Lead Academic Participating Site with the following Specific Aims: 1. To enhance the quality off scientific and administrative leadership in the development and conduct of clinical trials across the NCTN; 2. To continue and improve our accrual to multi-center clinical
trials at UPCI; To continue and improve processes for rapid activation of new trials at UPCI.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
NCI NCTN-Network Lead Academic Participating Site at UPMC Hillman Cancer Center
-
批准号:10733571
-
项目类别:
-
资助金额:$4.0万
-
财政年份:2022
-
负责人:ADAM M BRUFSKY
-
依托单位:
NCI NCTN-Network Lead Academic Participating Site at UPMC Hillman Cancer Center
-
批准号:10116973
-
项目类别:
-
资助金额:$91.11万
-
财政年份:2019
-
负责人:ADAM M BRUFSKY
-
依托单位:
NCI NCTN-Network Lead Academic Participating Site at UPMC Hillman Cancer Center
-
批准号:10582598
-
项目类别:
-
资助金额:$91.11万
-
财政年份:2019
-
负责人:ADAM M BRUFSKY
-
依托单位:
NCI NCTN-Network Lead Academic Participating Site at UPMC Hillman Cancer Center
-
批准号:10359765
-
项目类别:
-
资助金额:$91.11万
-
财政年份:2019
-
负责人:ADAM M BRUFSKY
-
依托单位:
NCI NCTN-Network Lead Academic Participating Site at UPMC Hillman Cancer Center
-
批准号:9923609
-
项目类别:
-
资助金额:$91.11万
-
财政年份:2019
-
负责人:ADAM M BRUFSKY
-
依托单位:
NCI NCTN-Network Lead Academic Site at UPCI
-
批准号:9024474
-
项目类别:
-
资助金额:$85.35万
-
财政年份:2014
-
负责人:ADAM M BRUFSKY
-
依托单位:
RHUMABHER2/CYCLOPHOSPHAMIDE/DOXORUBICIN AND PLACEBO/CYCLOPHOSPHAMIDE/DOXORUCINB
-
批准号:6304687
-
项目类别:
-
资助金额:$0.3万
-
财政年份:1999
-
负责人:ADAM M BRUFSKY
-
依托单位:
SAFETY STUDY OF RECOMBINANT MONOCLONAL ANTIBODY
-
批准号:6304653
-
项目类别:
-
资助金额:$0.3万
-
财政年份:1999
-
负责人:ADAM M BRUFSKY
-
依托单位:
RECOMBINANT HUMANIZED ANTI-185HER2 MONOCLONAL ANTIBODY IN BREAST CANCER
-
批准号:6304677
-
项目类别:
-
资助金额:$0.3万
-
财政年份:1999
-
负责人:ADAM M BRUFSKY
-
依托单位:
RHUMABHER2/CYCLOPHOSPHAMIDE/DOXORUBICIN AND PLACEBO/CYCLOPHOSPHAMIDE/DOXORUCINB
-
批准号:6219253
-
项目类别:
-
资助金额:$0.3万
-
财政年份:1998
-
负责人:ADAM M BRUFSKY
-
依托单位:
SAFETY STUDY OF RECOMBINANT MONOCLONAL ANTIBODY
-
批准号:6264180
-
项目类别:
-
资助金额:$0.3万
-
财政年份:1998
-
负责人:ADAM M BRUFSKY
-
依托单位:
RECOMBINANT HUMANIZED ANTI-185HER2 MONOCLONAL ANTIBODY IN BREAST CANCER
-
批准号:6219239
-
项目类别:
-
资助金额:$0.3万
-
财政年份:1998
-
负责人:ADAM M BRUFSKY
-
依托单位:
LIPOSOMAL ANNAMYCIN IN TAXANE RESISTANT BREAST CANCER
-
批准号:6264179
-
项目类别:
-
资助金额:$0.3万
-
财政年份:1998
-
负责人:ADAM M BRUFSKY
-
依托单位:
RECOMBINANT HUMANIZED ANTI-185HER2 MONOCLONAL ANTIBODY IN BREAST CANCER
-
批准号:6275815
-
项目类别:
-
资助金额:$1.91万
-
财政年份:1997
-
负责人:ADAM M BRUFSKY
-
依托单位:
Cancer Therapeutics Program
-
批准号:10024353
-
项目类别:
-
资助金额:$5.68万
-
财政年份:1997
-
负责人:ADAM M BRUFSKY
-
依托单位:
Cancer Therapeutics Program
-
批准号:10254113
-
项目类别:
-
资助金额:$5.12万
-
财政年份:1997
-
负责人:ADAM M BRUFSKY
-
依托单位:
Cancer Therapeutics Program
-
批准号:10674880
-
项目类别:
-
资助金额:$5.77万
-
财政年份:1997
-
负责人:ADAM M BRUFSKY
-
依托单位:
RHUMABHER2/CYCLOPHOSPHAMIDE/DOXORUBICIN AND PLACEBO/CYCLOPHOSPHAMIDE/DOXORUCINB
-
批准号:6275829
-
项目类别:
-
资助金额:$1.91万
-
财政年份:1997
-
负责人:ADAM M BRUFSKY
-
依托单位:
Cancer Therapeutics Program
-
批准号:10474536
-
项目类别:
-
资助金额:$5.77万
-
财政年份:1997
-
负责人:ADAM M BRUFSKY
-
依托单位:
ANDROGEN RECEPTOR ASSOCIATED PROTEINS IN PROSTATE CANCER
-
批准号:2111821
-
项目类别:
-
资助金额:$7.66万
-
财政年份:1995
-
负责人:ADAM M BRUFSKY
-
依托单位:
海外基金